The results demonstrated that CLL patients with low TCF1 expression have a shorter TTFT (5-year TTFT rate: 36% vs. 57%, P = 0.009; Figure 2E) and OS (5-year OS rate: 28% vs. 98%, P < 0.001; Figure 2F) than those with high TCF1 expression. The gene discussed is TCF7; the disease is B-cell chronic lymphocytic leukemia.